NO921119D0 - Inhibering av transformerende vekstfaktor beta for aa forhindre akkumulering av ekstracellulaer matriks - Google Patents

Inhibering av transformerende vekstfaktor beta for aa forhindre akkumulering av ekstracellulaer matriks

Info

Publication number
NO921119D0
NO921119D0 NO921119A NO921119A NO921119D0 NO 921119 D0 NO921119 D0 NO 921119D0 NO 921119 A NO921119 A NO 921119A NO 921119 A NO921119 A NO 921119A NO 921119 D0 NO921119 D0 NO 921119D0
Authority
NO
Norway
Prior art keywords
pathologies
growth factor
extracellular matrix
beta
transforming growth
Prior art date
Application number
NO921119A
Other languages
English (en)
Norwegian (no)
Other versions
NO921119L (no
Inventor
Wayne A Border
Erkki I Ruoslahti
Original Assignee
Jolla Cancer Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jolla Cancer Res Found filed Critical Jolla Cancer Res Found
Publication of NO921119L publication Critical patent/NO921119L/no
Publication of NO921119D0 publication Critical patent/NO921119D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
NO921119A 1989-09-29 1992-03-20 Inhibering av transformerende vekstfaktor beta for aa forhindre akkumulering av ekstracellulaer matriks NO921119D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41508189A 1989-09-29 1989-09-29
US41665689A 1989-10-03 1989-10-03
PCT/US1990/005566 WO1991004748A1 (en) 1989-09-29 1990-09-27 INHIBITING TRANSFORMING GROWTH FACTOR β TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX

Publications (2)

Publication Number Publication Date
NO921119L NO921119L (no) 1992-03-20
NO921119D0 true NO921119D0 (no) 1992-03-20

Family

ID=27022856

Family Applications (1)

Application Number Title Priority Date Filing Date
NO921119A NO921119D0 (no) 1989-09-29 1992-03-20 Inhibering av transformerende vekstfaktor beta for aa forhindre akkumulering av ekstracellulaer matriks

Country Status (10)

Country Link
EP (2) EP0494264B1 (de)
JP (1) JPH0780780B2 (de)
AT (1) ATE154514T1 (de)
AU (1) AU654938B2 (de)
CA (1) CA2065860C (de)
DE (1) DE69030956T2 (de)
DK (1) DK0494264T3 (de)
FI (1) FI921353A0 (de)
NO (1) NO921119D0 (de)
WO (1) WO1991004748A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
DE69228700T2 (de) * 1991-12-04 1999-09-09 Jolla Cancer Res Found Verwendung von Decorin oder Biglycan zur Herstellung eines Medikaments für die Behandlung von Diabetes-bedingter Zustände
GB9205800D0 (en) * 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
AU3943793A (en) * 1992-04-01 1993-11-08 Whittier Institute For Diabetes And Endocrinology, The Methods of inhibiting or enhancing scar formation in the CNS
US5395825A (en) * 1993-03-10 1995-03-07 Yale University Fertility regulation with transforming growth factor β
US5453492A (en) * 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
ATE315939T1 (de) * 1993-11-19 2006-02-15 Univ Sydney Verfahren zur prophylaxe oder kontrolle des katarakts
EP0754058B1 (de) * 1994-03-29 1999-11-03 The Victoria University Of Manchester Wundheilung
EP1741780A3 (de) * 1995-06-02 2007-03-28 Gilead Sciences, Inc. Ologonukleotidliganden mit höher Affinität für Wachstumsfaktoren
GB2304045A (en) † 1995-08-04 1997-03-12 Univ Manchester Betaglycan compositions for promoting the healing of wounds and fibrotic diseases
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
GB9601081D0 (en) * 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
AU2008200019B2 (en) * 1999-01-05 2009-10-08 American National Red Cross Methods for treating conditions associated with the accumulation of excess extracellular matrix
EP1140041A2 (de) * 1999-01-05 2001-10-10 University of Utah Research Foundation Verfahren zur behandlung von mit der akkumulation der extrazellulären matrix-assozierten störungen
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
CA2400628A1 (en) 2000-03-09 2001-09-13 Genzyme Corporation Use of tgf-beta antagonists to treat or to prevent loss of renal function
JP4566605B2 (ja) * 2004-04-02 2010-10-20 有限会社開発顧問室 短鎖ペプチドを有効成分とするコラーゲン合成阻害剤およびその製造方法
JP2009221164A (ja) 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
HUE048419T2 (hu) 2004-12-22 2020-08-28 Nitto Denko Corp Gyógyszerhordozó és kit gyógyszerhordozó kit fibrózis gátlására
EP1948675B1 (de) 2005-10-25 2014-07-30 The Johns Hopkins University Verfahren und zusammensetzungen zur behandlung von marfan-syndrom und verwandten erkrankungen
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
EP2230252A1 (de) 2006-03-13 2010-09-22 The Johns Hopkins University Erhöhung der endothelialen Thromboresistenz
EP3254696A1 (de) 2006-10-03 2017-12-13 Genzyme Corporation Verwendung von tgf-beta-antagonisten zur behandlung von kleinkindern mit dem risiko des ausbruchs von bronchopulmonaler dysplasie
JP5950428B2 (ja) 2010-08-05 2016-07-13 日東電工株式会社 線維化組織から正常組織を再生するための組成物
CA2823154A1 (en) 2010-12-27 2012-07-05 Lsip, Llc Ips cells and method for generating same
KR102051014B1 (ko) 2011-06-03 2019-12-04 조마 테크놀로지 리미티드 Tgf-베타에 특이적인 항체
WO2013014262A1 (en) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating myhre syndrome
MX2014004994A (es) 2011-10-26 2014-08-27 Seattle Children S Res Inst Cisteamina en el tratamiento de enfermedad fibrotica.
EP2799537B1 (de) 2011-12-28 2021-09-22 Kyoto Prefectural Public University Corporation Normalisierung der züchtung von hornhautendothelzellen
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
EP3064222B1 (de) 2013-10-31 2020-10-21 Kyoto Prefectural Public University Corporation Therapeutikum enthaltend einen tgf-beta signalblocker für erkrankungen im zusammenhang mit endoplasmatischem retikulumszelltod im hornhautendothel
EP3127915B1 (de) 2014-04-02 2020-08-26 Nitto Denko Corporation Von rbp-abstammendes zielmolekül und verwendung davon
CN106133024B (zh) 2014-04-07 2019-07-05 日东电工株式会社 用于疏水性药物递送的新颖的基于聚合物的助水溶物
US10092891B2 (en) 2014-04-25 2018-10-09 University Of Florida Research Foundation, Incorporated Controlling the activity of growth factors, particularly TGF-β, in vivo
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
CN109862914A (zh) * 2016-09-30 2019-06-07 中央研究院 微核糖核酸let-7及转化生长因子β第三类受体调控轴作为心脏损伤靶标的用途
WO2021018923A1 (en) 2019-07-31 2021-02-04 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Peptides as inhibitors of fibrotic matrix accumulation
EP3771464A1 (de) 2019-07-31 2021-02-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Peptide als inhibitoren der fibrotischen matrixakkumulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352664A (en) * 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
US5384309A (en) * 1989-07-17 1995-01-24 Genentech, Inc. Cyclized peptides and their use as platelet aggregation inhibitors

Also Published As

Publication number Publication date
AU654938B2 (en) 1994-12-01
NO921119L (no) 1992-03-20
ATE154514T1 (de) 1997-07-15
EP0494264A1 (de) 1992-07-15
FI921353A (fi) 1992-03-27
EP0494264B1 (de) 1997-06-18
EP0775742A2 (de) 1997-05-28
DE69030956D1 (de) 1997-07-24
WO1991004748A1 (en) 1991-04-18
JPH05503076A (ja) 1993-05-27
AU6612590A (en) 1991-04-28
EP0775742A3 (de) 1998-01-14
DK0494264T3 (da) 1998-01-26
CA2065860A1 (en) 1991-03-30
CA2065860C (en) 2001-03-27
DE69030956T2 (de) 1998-01-15
FI921353A0 (fi) 1992-03-27
JPH0780780B2 (ja) 1995-08-30

Similar Documents

Publication Publication Date Title
NO921119L (no) Inhibering av transformerende vekstfaktor beta for aa forhindre akkumulering av ekstracellulaer matriks
IT8619684A0 (it) Preparato di acido ialuronico chimicamente modificato e metodo per recuperarlo da tessuti animali.
PT74357B (en) Process for preparing aromatic heterocyclic esters of steroids
ES2114065T3 (es) Metodo para el diagnostico y control de la sepsis.
SE9500620D0 (sv) Anordning för hjärtstimulering
FR2517195B1 (fr) Dispositif de reduction et de correction externes pour le traitement de fractures osseuses
RU94016354A (ru) Новые полипептидные соединения, способ их получения, фармацевтическая композиция, способ лечения
ES2062241T3 (es) Metodo de purificacion de la albumina serica humana.
DE3873855D1 (de) Mischung von cholecalciferol-derivaten fuer die behandlung von nierenbezogenen knochenkrankheiten.
McGaugh et al. Amnesic and punishing effects of electroconvulsive shock
PT69525A (fr) Installation de traite d'animaux en particulier des brebis
CA2074166A1 (en) Method for treating intestinal diseases
NO922573L (no) Fremgangsmaate for aa paavise ben- og andre bindevevsforstyrrelser hos mennesker og dyr
Huxley et al. Striation patterns in active and passive shortening of muscle
Schweigerdt et al. Alcohol and evoked potentials in the cat
NO882373L (no) Fremgangsmaate for silicopyrohydrolysebehandling av bruktehall-heroult-elektrolysetanker.
NO147232C (no) Fremgangsmaate for aa forbedre den biologiske taalbarhet av polyamidimplanteringsproteser
FR2585020B1 (fr) Nouvelle substance biologiquement active, appelee girolline, extraite de l'eponge pseudaxinyssa cantharella, son procede de preparation et les compositions pharmaceutiques qui la contiennent
Coover et al. Corticosterone levels during avoidance learning in rats with cingulate lesions suggest an instrumental reinforcement deficit.
EP0367744A3 (en) Supporting device for cleaning animals with fur, product and procedure for cleaning animals with fur
IT1223017B (it) Procedimento per il trattamento dei telai di arnie disopercolati e paniere per l'attuazione di tale procedimento
DK0409999T3 (da) Anvendelse af L-ascorbin-2-phosphat-syre eller et farmaceutisk acceptabelt salt deraf til fremstilling af en skylleopløsning til hindring af skader op intraokulart væv
Schellenberg et al. The method of nasopharyngeal EEG recording from structures near the hippocampus in schizophrenic patients and normals
IT8944004A0 (it) Procedimento per l'impianto di trattamento totale dei fumi provenienti da processi di combustione
BE869147A (fr) Procede pour eliminer l'attaque des cathodes au niveau de la solution pendant l'electrolyse